00:11 , Mar 10, 2017 |  BC Innovations  |  Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Structural analyses of polycomb repressive complex 2 (PRC2) bound to an inhibitor and a mutant histone H3 substrate

Drug platforms TECHNOLOGY: Structural analyses Structural analyses of PRC2 bound to an inhibitor or histone H3 substrate could help guide the development of PRC2 inhibitors for cancer that bypass known mechanisms of resistance. Analysis of...